Sex‐specific changes in GLP ‐ 1RA trends (2019–2024): Impact of FDA approval of semaglutide (Wegovy) for chronic weight management in the United States
Main finding · GLP-1RA utilization, adultsResult — go to the resultRelative risk 2.68Authors' conclusion
The FDA approval of semaglutide (Wegovy) for chronic weight management was associated with a sharp increase in GLP-1RA utilization in the United States, widening sex-based differences, with female utilization significantly surpassing that of males.
Study context
- Population
- Individuals in US MarketScan commercial claims data, 2019–2024; 30 months before and 31 months after FDA approval
- Comparison
- Females vs males, before and after FDA approval of semaglutide (Wegovy) for chronic weight management (June 2021)
- Outcome
- Monthly GLP-1RA utilization rate (users per 10 000 eligible individuals); RR comparing post-intervention slope changes between males and females
Methodological detailssegmented regression, 2019-2024 MarketScan commercial claims data
- Segmented regression
- 2019-2024 MarketScan commercial claims data
Main finding
GLP-1RA utilization, adults · January 2024
Relative risk
2.68
By group
As reported in the abstract
Further findings
GLP-1 RA utilization, adolescents · January 2024
RR 2.74
GLP-1 RA utilization, nondiabetic patients · January 2024
RR 2.86
GLP-1 RA utilization, diabetic patients · January 2024
RR 2.2
Wegovy utilization · January 2024
RR 4.03
Ozempic utilization · January 2024
RR 2.13
Mounjaro utilization · January 2024
RR 1.74
Pre-intervention GLP-1 RA utilization trends · before June 2021
- Similar utilization trends among males and females before the intervention, overall and in subgroups
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →